The capital is pricing Ascentage Pharma's APG-2575 (lisaftoclax) at a valuation that assumes global first-wave approval: the Shenzhen-listed entity trades at roughly 18x forward book after the HK listing reactivation in Q2 2026, and the pipeline narrative centres on a CLL indication with a clean BH3-mimetic mechanism. The clinical ledger is narrower. The pivotal DAWNING-1 trial in relapsed/refractory CLL enrolled 212 patients; the primary endpoint was investigator-assessed overall response rate, a surrogate that NMPA's Center for Drug Evaluation accepted under the priority review track for haematologic malignancies, but that TGA's Advisory Committee on Prescription Medicines has historically treated as insufficient for accelerated registration without a planned overall-survival readout. No OS data is scheduled before 2028.

NMPA granted conditional approval in April 2026 under Article 31 of the 2019 Drug Administration Law, which requires post-marketing confirmatory trials within five years. The confirmatory protocol has not been posted to the Chinese Clinical Trial Registry as of the June 2026 cutoff. The capital is pricing global label expansion. The clinical ledger holds one conditional domestic approval on a surrogate endpoint, a TGA pathway that requires evidence the current trial was not designed to generate, and a confirmatory obligation that has not yet been converted into a registered study. Family-office positions treating the NMPA conditional as a proxy for TGA clearance are pricing two different regulatory architectures as one instrument; the Article 31 post-market clock started in April 2026 and the first confirmatory study enrollment target will be the next observable fact.